Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision OncologyGlobeNewsWire • 10/16/26
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR SymposiumGlobeNewsWire • 09/22/26
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/10/26
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsGlobeNewsWire • 08/28/26
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026GlobeNewsWire • 07/30/26
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid TumorsGlobeNewsWire • 06/01/26
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/21/26
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/13/26
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingGlobeNewsWire • 04/21/26
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementGlobeNewsWire • 04/01/26
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 TrialGlobeNewsWire • 03/30/26
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/16/26
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialGlobeNewsWire • 02/18/26
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/17/26
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline GrowthGlobeNewsWire • 02/12/26
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical AdvisorGlobeNewsWire • 02/04/26
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First ScanGlobeNewsWire • 01/29/26
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 01/29/26
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026GlobeNewsWire • 12/18/25